TFS Capital’s Lifecore Biomedical LFCR Stock Holding History

TFS Capital’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-150,224	Closed	-$1.75M	–	827
2015 Q3	$1.75M	Buy	150,224 +79,222	+112%	+$1.05M	0.17%	192
2015 Q2	$1.02M	Buy	+71,002	New	+$1.02M	0.1%	329
2014 Q1	–	Sell	-25,384	Closed	-$308K	–	1475
2013 Q4	$308K	Buy	+25,384	New	+$303K	0.01%	1082
2013 Q3	–	Sell	-13,349	Closed	-$176K	–	1532
2013 Q2	$176K	Buy	+13,349	New	+$185K	0.01%	1358

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

NIMC

NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

TFS Capital's LFCR Position: Q4 2015 in Review

TFS Capital sold out of Lifecore Biomedical (LFCR) in Q4 2015, closing a stake of 150,224 shares — an estimated $1.75M sold.

TFS Capital first reported a position in LFCR in Q2 2013 and held it in 4 quarters. The position peaked at $1.75M in Q3 2015. 109 funds tracked by Wall St. Rank hold LFCR as of Q4 2015.

TFS Capital reported no remaining Lifecore Biomedical position as of Q4 2015 after selling out during the quarter.
TFS Capital sold 150,224 Lifecore Biomedical shares in Q4 2015, an estimated $1.75M.
TFS Capital first reported a position in Lifecore Biomedical in Q2 2013 and held it in 4 quarters.
TFS Capital's Lifecore Biomedical position peaked at $1.75M in Q3 2015.
109 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2015.

Based on TFS Capital's 13F filing for Q4 2015, filed 29 Jan 2016.